Self-Assembled Type I Nanophotosensitizer with NIR-II Fluorescence Emission for Imaging-Guided Targeted Phototherapy of Glioblastoma

Yuyang Zhang,Min Zhao,Diedie Cheng,Jieli Zhu,Baoliang Cheng,Minqian Miao,Qing Li,Qingqing Miao
DOI: https://doi.org/10.1021/acsanm.4c04201
IF: 6.14
2024-01-01
ACS Applied Nano Materials
Abstract:Glioblastoma (GBM) is the most formidable primary brain tumor in adults, and its treatment remains a great challenge. Photodynamic therapy (PDT) provides a promising and noninvasive method to combat GBM with low side effects and ignorable resistance, but it is hampered by the hypoxic environment of GBM and the presence of the blood-brain barrier (BBB). Herein, we report a low-O2-dependent type I photosensitizer (LTPA) self-assembly endowed with BBB-crossing ability for near-infrared II (NIR-II) fluorescence imaging-guided photodynamic/photothermal therapy (PDT/PTT) of GBM. LTPA is constructed with an optimized type I photosensitizer conjugated with a BBB-crossing and GBM-targeting ligand angiopep-2 through a poly(ethylene glycol) (PEG) linker, which can self-assemble to form nanoparticles in aqueous solution. Under 808 nm laser irradiation, LTPA nanoparticles display an NIR-II fluorescence emission and an effective type I process to generate O2 center dot- alongside commendable photothermal conversion, which enables LTPA nanoparticles to exert outstanding photocytotoxicity under both normoxic and hypoxic environments. With the aid of angiopep-2 and the synergistic PDT/PTT effect, LTPA nanoparticles can actively accumulate at the tumor site and efficiently suppress the growth of orthotopic GBM in living mice. Therefore, this work presents a potential design tactic for constructing type I PDT/PTT photosensitizers for the effective treatment of hypoxic GBM.
What problem does this paper attempt to address?